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Poly(ADP-ribose) polymerase (Parp) is an enzyme responsible for catalyzing post-
translational modifications through the addition of poly(ADP-ribose) chains (known as
PARylation). Modification by PARylation modulates numerous cellular processes includ-
ing transcription, chromatin remodeling, apoptosis, and DNA damage repair. In particular,
the role of Parp activation in response to DNA damage has been intensely studied.Tumors
bearing mutations of the breast cancer susceptibility genes, Brca1/2, are prone to DNA
breakages whose restoration into functional double-strand DNA is Parp dependent. This
concept has been exploited therapeutically in Brca mutated breast and ovarian tumors,
where acute sensitivity to Parp inhibitors is observed. Based on in vitro and clinical stud-
ies it remains unclear to what extent Parp inhibitors can be utilized beyond treating Brca
mutated tumors.This review will focus on the often overlooked roles of PARylation in chro-
matin remodeling, epigenetics, and transcription to explain why some cancers may be
unresponsive to Parp inhibition. We predict that understanding the impact of PARylation
on gene expression will lead to alternative approaches to manipulate the Parp pathway for
therapeutic benefit.
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THE CLINICAL LANDSCAPE OF Parp INHIBITORS AS
ANTI-CANCER THERAPEUTICS
Breast cancer is an epidemic afflicting approximately one out of
every nine women (Kurian et al., 2010). This heterogeneous disease
is clinically stratified into four major subtypes; luminal A, luminal
B, Her2+ [elevated Her2, Estrogen receptor (ER) negative], and
triple-negative (Her2, ER, and progesterone receptor negative).
However, current literature indicates further stratification using
additional clinical markers, such as cytokeratins, Cyclin D1, and
Claudin (Gusterson et al., 2005; Prat et al., 2010; Curtis et al., 2012),
will provide more precise prognostic and predictive information.
Patients whose tumors fall into the triple-negative category have
the poorest clinical outcomes. While these aggressive tumors ini-
tially respond to chemotherapy, triple-negative patients are at high
risk for metastatic recurrence and have poor overall survival (Di
Cosimo and Baselga, 2010). Clearly, new therapeutic strategies are
desperately needed to combat triple-negative tumors both at the
time of onset and if necessary, at recurrence.
Approximately 10–20% of triple-negative tumors harbor a
mutation in the Brca1/2 genes (Gonzalez-Angulo et al., 2011;
Pern et al., 2012; Phuah et al., 2012). Brca1/2 proteins are an inte-
gral part of the homologous-recombination (HR) mediated DNA
damage repair process. When mutated, the repair of double-strand
breaks by HR is compromised. Mutations within the Brca genes
are known to confer a 50–80% lifetime risk of breast cancer and
a 20–40% lifetime risk of ovarian cancer for female carriers (Ford
et al., 1998). An exciting new development in the field of cancer
therapy is the exploitation of this defect using Poly(ADP-ribose)
polymerase (Parp) inhibitors to generate synthetic lethality. Parp
inhibitors have been used successfully to achieve clinical responses
in patients with Brca mutated breast or ovarian cancers (Fong et al.,
2009; Audeh et al., 2010; Tutt et al., 2010). Notably, the adverse
effects of Parp inhibitors seen in clinical trials are quite mild with
few signs that non-tumorigenic tissue is targeted by these drugs.
The role of Parp in the DNA damage repair response is
multifaceted and already well-reviewed (Aly and Ganesan, 2011;
Helleday, 2011). It is generally suggested throughout the sci-
entific literature that Parp inhibitors generate an accumulation
of single-strand DNA breaks in Brca mutated cells, which are
subsequently processed to double-strand breaks during replica-
tion. However, the precise mechanism whereby Brca mutations
and Parp inhibition combine to create a synthetic lethal effect
remains somewhat controversial, with multiple mechanisms pro-
posed (Helleday, 2011). Nonetheless, it seems clear that Parp
inhibitors lead to stalled replication forks and an accumulation
of DNA damage, particularly cytotoxic in cells with a mutant Brca
background.
The clinical efficacy of Parp inhibitors in triple-negative breast
tumors bearing Brca mutations has sparked interest to initiate
new clinical trials in triple-negative patients having wild-type
Brca with the expectation that combining chemotherapy with
Parp inhibitors will enhance the outcomes of currently utilized
therapies. While the results from a few phase one trials are
encouraging, to date, most have been met with limited success.
Preliminary data from a cohort of 86 triple-negative patients co-
treated with the Parp inhibitor Bsi-201 (iniparib) and gemcitabine
showed improved overall survival (O’Shaughnessy et al., 2009).
Similarly, co-treatment of a 123 triple-negative patient cohort
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with gemcitabine and iniparib improved overall survival from 7.7
to 12.3 months (O’Shaughnessy et al., 2011). But a larger phase
III trial involving 519 women showed co-treatment of cytotoxic
agents with the Parp inhibitor Iniparib was associated with dis-
ease progression in most cases (O’Shaughnessy, 2011). However,
results from these trials should be taken with caution as recent data
suggests Parp is not the primary target of iniparib (Liu et al., 2012).
Another phase II trial looking at the efficacy of the Parp inhibitor
olaparib in breast cancer patients failed to show significant clinical
responses (Gelmon et al., 2011). Encouragingly, in this same study,
a cohort of patients with ovarian cancers did demonstrate partial
responses to olaparib regardless of Brca status.
Overall, the early indicators from trials involving Parp
inhibitors for triple-negative breast cancer show partial, but not
complete responses. Encouragingly, there are clearly patients who
do respond to these therapies. Recent research has identified a
subset of triple-negative tumors that have an increased likelihood
to respond to Parp inhibition. Defective proteins in the HR repair
system, or epigenetically silenced Brca, amongst other defects, con-
tribute to a molecular pathology that is not unlike tumors bearing
Brca mutations. These tumor properties are defined as having
“Brcaness” or being “Brca-like” (Turner et al., 2004; Ratner et al.,
2012). This concept has led to the hypothesis that tumors with
features of Brcaness may respond to Parp inhibition. The con-
cept of Brcaness has been used in retrospective study to predict
response to platinum-based therapies in 8 of 10 patients (Kon-
stantinopoulos et al., 2010). But a recent study analyzing data
from 101 patients receiving adjuvant cyclophosphamide-based
chemotherapy showed Brcaness could not predict differences in
patient survival (Oonk et al., 2012). However, it still remains
to be determined if pathological features of Brcaness may be a
more powerful predictor of sensitivity to Parp inhibitors than
conventional chemotherapy.
Current literature suggests several hypotheses to predict sen-
sitivity to Parp inhibition in subsets of triple-negative tumors,
but there is a lack of evidence from in vitro and mouse studies
suggesting that established triple-negative cell lines are sensitive
to clinically relevant Parp inhibitors or Parp-1 knock down. In
fact, unpublished data from our lab and another recent report
show very high concentrations of commonly used Parp inhibitors
are needed to suppress the growth of triple-negative cell lines
in vitro (Chuang et al., 2012). The micromolar concentrations
of inhibitors needed to suppress proliferation is likely well beyond
those required to block Parp activity (Bryant et al., 2005; Liu et al.,
2008), and may reflect secondary effects of these inhibitors.
Beyond breast cancer, early phase clinical trials with Parp
inhibitors in combination with standard chemotherapy have been
met with either partial responses, or a lack of clinically rel-
evant responses in multiple types of solid tumors (Plummer
et al., 2008; Khan et al., 2011; Kummar et al., 2011, 2012; Rajan
et al., 2012). We propose that activities of Parp, being targeted
by inhibitors beyond those in the DNA damage repair process,
account for their limited success in a wild-type Brca background
(Figure 1). Specifically, we hypothesize that targeting Parp will
impair its role in regulating the expression of tumor suppressor
genes, thereby generating unwanted consequences. However, we
further propose that understanding the mechanisms whereby Parp
activates transcription may be used to predict new, more potent
therapeutic approaches.
POLY(ADP)POLYMERASES, MORE THAN DNA REPAIR
ENZYMES
The Parp family of enzymes encompasses multiple proteins (up
to 17) of varying degrees of homology (with the main conser-
vation residing in the Parp catalytic domain), all of whom use
NAD+ as a substrate to catalyze the addition of ADP-ribose moi-
eties onto target proteins (Kim et al., 2005). Among the Parp
proteins, only Parp-1 and Parp-2 build “poly” ADP-ribose poly-
mers. The other family members, including Parp-3, are capable of
adding only a monomeric ADP-ribose to proteins. Of Parp-1 and
2, Parp-1 has been more extensively studied and will therefore be
the focus of this review. Under basal conditions, Parp-1 is active,
but modifies relatively few target proteins compared to conditions
of cellular stress and after DNA damage (Gagne et al., 2008, 2012;
Witcher and Emerson, 2009). Parp-1 recognizes and binds specific
DNA secondary structures commonly associated with damaged
DNA including single-strand DNA, double-strand breaks, and
crossovers. Upon binding, its enzymatic activity is allosterically
triggered (D’Amours et al., 1999; Kun et al., 2002). This particular
mechanism of regulation allows localized activation of Parp-1 for
targeted repair of DNA damage. However, numerous studies have
also demonstrated that Parp-1 is recruited to chromatin, which
acts as an on-switch for its enzymatic activity in the absence of
DNA damaging agents (Poirier et al., 1982; Ding and Smulson,
1994; Kim et al., 2004; Lonskaya et al., 2005; Pinnola et al., 2007;
Wacker et al., 2007).
Parp-1 associates with the chromatin of promoter regions in a
significant proportion of actively transcribed genes throughout the
genome (Krishnakumar and Kraus, 2010; Zhang et al., 2012) and
copurifies biochemically with RNA Pol II (Slattery et al., 1983).
Consistent with this, multiple studies utilizing Parp-1 depleted
cells have substantiated an activating role for Parp-1 in gene reg-
ulation (Ziegler and Oei, 2001; Ogino et al., 2007; Krishnakumar
et al., 2008; Okada et al., 2008; Frizzell et al., 2009).
How does Parp modulate gene expression? It does so through
a multi-pronged approach, with individual actions cooperating to
fine tune the transcriptional process (Figure 1). Parp-1 regulates
transcription minimally through (1) the alteration of chromatin
structure (2) the control of DNA and histone methylation status
(3) the recruitment and maintenance of transcription factors to
promoter regions, and (4) acting as a transcriptional coregulator.
Parp-1 AS A REGULATOR OF TRANSCRIPTION
First, direct PARylation of histones can lead to a loosening of
chromatin conformation. PARylation of bulk nucleosomes in vitro
leads to decondensation (Faraone-Mennella et al., 1993) and Parp
activity is required for chromatin loosening at stress induced
genes in Drosophila (Tulin and Spradling, 2003). Biochemically,
the negative charge conferred by the PAR group onto histones
promotes their release from the DNA due to charge repulsion.
Such is the case for histone H1, a heterochromatin-promoting fac-
tor whose PARylation-dependent removal from chromatin serves
to promote chromatin relaxation (Poirier et al., 1982; Huletsky
et al., 1989). Interestingly, Parp-1 localization is inversely related
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FIGURE 1 | Epigenetic and transcriptional impact of Parp inhibitors. Parp
inhibitors may contribute to epigenetic and transcriptional deregulation in cells
through several different mechanisms. (A)The drug-induced spread of
heterochromatin may result from the release of the protein Iswi from
inhibition, promoting histone H1 integration into chromatin, and through the
prevention of histone H1 removal from chromatin by direct PARylation. (B)
Chromatin boundaries normally maintained by PARylated Ctcf may be
disrupted and demethylation of H3K4me3 by Kdm5b restored with the use of
Parp inhibitors. In both incidencies, transcriptional inhibition will ensue. Such
drugs may also act to restore Dnmt1 methylation of DNA, further promoting
gene silencing. (C) Parp inhibition can disrupt protein: DNA interactions,
preventing the maintenance of certain trans-activating factors (e.g., Nfat) at
transcription start sites while also causing the retention of some repressor
proteins (e.g., Dek). (D) Gene activation may also be negatively regulated by
preventing Parp from acting as a transcriptional coregulator and obstructing
the recruitment of such proteins as the histone acetyl transferase p300.
to histone H1 binding throughout the genome and higher pro-
portions of Parp-1:H1 proteins tend to indicate active promoters
(Krishnakumar et al., 2008). Consistent with this, experiments
using Parp-1 mutants and Parp inhibitors in Drosophila revealed
more pronounced heterochromatin at the Heat shock protein 70
(Hsp70) locus (Tulin and Spradling, 2003). Likewise, an RNAi
screen revealed Parp is necessary for nucleosome eviction from
chromatin at the Hsp70 locus during the rapid gene induction
response to heat shock (Petesch and Lis, 2008). Recently, it has
been demonstrated that lipopolysaccharide-induced Parp activity
displaces nucleosomes from target genes, thereby facilitating tran-
scription, as trans-activating factors will not have to contend with
the physical obstacle of dense nucleosomes at these promoters
(Martinez-Zamudio and Ha, 2012). In sum, the ability of Parp-1
to remodel chromatin in a manner conducive to transcriptional
activation strongly suggests that Parp-1 primarily acts as a potent
activator of transcription. However, in some contexts, Parp-1 may
promote a repressed chromatin conformation when enzymatically
inactive, and a more loose structure upon activation (Wacker et al.,
2007). At a subset of promoters, under unstimulated conditions,
Parp-1 presents itself in a corepressor complex with nucleolin,
nucleophosmin, and Hsp70. These repressive factors, however, are
released upon signal activation of Parp-1, thus providing a mech-
anism for differential effects of Parp-1 on chromatin structure (Ju
and Rosenfeld, 2006).
Countering the effects of PARylation on chromatin structure is
poly(ADP-ribose) glycohydrolase (known as Parg). Parg catabo-
lizes ADP-ribose polymers synthesized by Parp-1. This enzymatic
activity has been demonstrated to impair Parp-mediated chro-
matin remodeling in vitro (Kim et al., 2004). Chromatin remod-
eling mediated by Parp-1 potentiates transcriptional activation
by the ER (Kim et al., 2004) and Parg was shown to suppress
estrogen-dependent transcription through blocking Parp activity.
Further work is required to elucidate the in vivo action of Parg on
chromatin structure.
In addition to histone H1 removal, Parp-1 configures chro-
matin through modification of proteins involved in remodeling
and organizing chromatin structure. PARylation generally results
in protein activation, but can also result in functional suppression
of chromatin remodelers. For example, PARylation is inhibitory
to the function of the repressive remodeling complex Iswi (Sala
et al., 2008). Iswi is known to promote the association between H1
www.frontiersin.org December 2012 | Volume 3 | Article 202 | 3
Lovato et al. PARP inhibitors and epigenetics
and DNA (Corona et al., 2007), thus illustrating a complemen-
tary mechanism by which PARylation results in a reduction of H1
binding to DNA.
Notably, Parp interaction with Brg-1 (SmarcA4), together with
histone deacetylases (Hdacs), results in a repressive complex, inac-
tivating the transcription of genes involved in cardiomyocyte dif-
ferentiation through deacetylation of histones (Hang et al., 2010).
Thus, in particular contexts, Parp-1 activity can relay transcrip-
tionally repressive signals. Conversely, this same study showed that
a Parp-1/Brg-1 complex devoid of Hdac could activate a separate
subset of genes. It remains to be seen if the PARylation of Brg-1
leads to gene activation in other tissue types.
In addition, other chromatin remodelers are modified by Parp-
1 under conditions of cellular stress (Gagne et al., 2008, 2012).
Proteomic studies have shown these to include TopoIIα, Brg-1,
TopoIIβ, HmgA1, Chd1, Chd5, and Snf2L1. Clearly, Parp activa-
tion relays a signal that is having a profound effect on chromatin
structure. However, the precise impact PARylation has on these
proteins, and the subsequent effects on transcription of their target
genes remains unknown.
Second, Parp activity regulates gene expression through con-
trol of epigenetic mechanisms including histone modification and
DNA methylation. Parp covalently modifies the epigenetic regu-
latory protein CCCTC binding factor (Ctcf; Yu et al., 2004). Ctcf
PARylation is important for its insulator activity, which functions
to prevent enhancers and repressors from acting on distal promot-
ers over long distances. Therefore, inhibition of Ctcf PARylation
will result in altered regulation of target genes through the aberrant
actions of distal regulatory regions.
Chromatin immunoprecipitation experiments and knockdown
studies indicate Ctcf plays an import role in the maintenance of
chromatin boundaries (Cuddapah et al., 2009; Witcher and Emer-
son, 2009). Repressive heterochromatin is the default state and,
unless constrained, will spread passively throughout a chromo-
some (Talbert and Henikoff, 2006). Chromatin boundaries form
a barrier prohibiting the spread of repressive chromatin. Inter-
estingly, Ctcf PARylation has been linked to the maintenance of
chromatin boundaries at tumor suppressor genes (Witcher and
Emerson, 2009; Farrar et al., 2010).
This is supported by unpublished data from our lab show-
ing Parp inhibitors lead to an accumulation of repressive histone
modifications, such as H3K27me3, at tumor suppressor genes. We
have also published that Parp-1 inhibition through knockdown,
or pharmacologic approaches, results in the transcriptional repres-
sion of the Rassf1a and p16 tumor suppressor genes (Witcher and
Emerson, 2009). Based on this data, it is not unexpected that Parp
inhibitors have been found to have transcriptionally repressive
effects on tumor suppressor genes (Witcher and Emerson, 2009;
Nguyen et al., 2011). However, it remains to be proven that these
negative effects are mediated by disruption of Ctcf function.
Beyond modulating its role as a chromatin boundary protein,
PARylation of Ctcf may act as a docking site for Dnmt1 bind-
ing (Zampieri et al., 2009, 2012). This interaction is thought to
act a molecular sponge, prohibiting Dnmt1 from methylating
regions surrounding Ctcf binding sites. Elegant studies utilizing
engineered mutations of endogenous Ctcf sites clearly show local-
ized accumulation of DNA methylation when Ctcf binding is
abolished (Pant et al., 2004; Davalos-Salas et al., 2011). How-
ever, it remains to be proven that the interaction between Ctcf
and Dnmt1 is pivotal for the capacity of Ctcf to prevent DNA
methylation. Nevertheless, this model again suggests that a loss
of Ctcf PARylation brought about by Parp inhibitors would result
in profound epigenetic changes and significant changes to gene
expression throughout the genome. Supporting this model is at
least one study showing that Parp inhibition does indeed result
in widespread accumulation of DNA methylation (Reale et al.,
2005).
In addition to epigenetic regulation through Ctcf,PARylation of
other target proteins organize chromatin structure through coor-
dinating the placement of histone modifications. This has been
most clearly demonstrated for the histone demethylase Kdm5b
(Krishnakumar and Kraus, 2010). Modification of Kdm5b by
Parp-1 allows H3K4me3 to persist in the promoter regions of
actively transcribed genes. H3K4me3 is important for loading
the PolII machinery at most, if not all, actively transcribed genes.
PARylation of Kdm5b prevents active demethylation of this mark
at Kdm5b target genes, thus promoting transcription. Knockdown
of Parp-1 potently blocks transcription of Kdm5b target genes
through this mechanism. Clearly, small molecule inhibitors or
Parp-1 would be expected to disrupt transcription in a similar
fashion.
Third, Parp activity controls the recruitment and maintenance
of transcription factors to promoter regions. As stated above,
classic experiments from the Roder lab demonstrate that Parp-
copurifies biochemically with RNA PolII (Slattery et al., 1983).
Follow up work showed Parp enhances the assembly of the preini-
tiation complex in vitro (Meisterernst et al., 1997). Surprisingly,
Parp activity has been demonstrated to be necessary to retain Pol
II at actively transcribed target genes (Zobeck et al., 2010). It is
postulated that PAR polymers creates a scaffold that retains Pol
II at gene loci. It is quite possible, but remains to be proven, that
PAR scaffolds act to retain transactivators at target genes as well.
The trans-activating factors Nfat, Klf8, and Tef-1 are associated
with, and activated by PAR polymers (Butler and Ordahl, 1999;
Olabisi et al., 2008; Lu et al., 2011). It is possible the mechanism
lies in the retention of these factors at target genes by (ADP)ribose
polymers.
In contrast to this model, PARylation of the transcriptional
repressor Dek by Parp-1 serves to evict Dek from chromatin,
ultimately promoting gene activation (Gamble and Fisher, 2007).
Thus, blocking the actions of repressors serves as another mecha-
nism through which Parp activates transcription.
Fourth, Parp-1 itself has also been described to act as a coregu-
lator of transcription. It is recruited to genes via interaction with
DNA binding factors. As a coregulator, Parp-1 can be integrated
into complexes having stimulatory effects on transcription medi-
ated by transcription factors such as NF-κβ and AP-2 (Li et al.,
2004). To complete the assembly of the NF-κβ activating complex,
Parp-1 is required for the integration of the histone acetyltrans-
ferase p300 (Hassa et al., 2003; Kaur et al., 2006), providing another
link between Parp-1 and histone modification. Parp-1 is also
a component of a coactivating complex responsible for driving
nuclear hormone receptor-mediated transcription in response to
estrogens and retinoids (Pavri et al., 2005; Ju et al., 2006).
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Docking with Parp-1 can also serve to enhanced phosphoryla-
tion of the associated transcription factor leading to heightened
trans-activating capabilities. This has been demonstrated for B-
Myb in a cell cycle dependent fashion (Cervellera and Sala, 2000;
Santilli et al., 2001) and Elk-1 in response to Erk-1 activation
(Cohen-Armon et al., 2007). These data indicate Parp activity links
intra and extracellular signaling events with gene induction.
Parp-1 knockdown studies show Parp activity also functions
to repress a subset of genes (Frizzell et al., 2009). Consistent with
this, PARylation of a number of transcription factors has been
described to prevent their interaction with DNA. This has been
described for Smads (after TGFβ stimulation; Lonn et al., 2010),
p53, and Sp1 (Kumari et al., 1998; Malanga et al., 1998; Zaniolo
et al., 2007). Inactivation of Smads by Parp following TGFβ signal-
ing remains controversial as a more recent study found Parp neces-
sary for Smad activation post-TGFβ exposure (Huang et al., 2011).
It will be of great interest in the future to determine how Parp inte-
grates signaling events such as TGFβ, reactive oxygen species, and
growth factors into coordinated transcriptional outputs.
Information from in vitro studies describing the inhibition
of transcription factor binding to cognate sites by PARylation
should be taken with caution. Without the constraints found
in vivo,ADP-ribose polymers can be extended to enormous lengths
in vitro (D’Amours et al., 1999; Mendoza-Alvarez et al., 2000). It
is likely that the formation of such a network of polymers could
impair binding to cognate DNA sites in vitro due to simple steric
hindrance.
Overall, evidence suggests that Parp-1 plays primarily a stim-
ulatory role on transcription, including activation of tumor sup-
pressor genes and a more minor role in gene repression. Clearly
there is overwhelming data demonstrating that Parp-1 participates
in gene regulation at multiple levels, most prominently by coor-
dinating transcription factor activity and organizing chromatin
structure. It is imperative that these aspects of Parp-1 function be
considered, along with its role in DNA damage repair if we are to
extend the clinical use of Parp inhibitors to treat tumors beyond
those bearing Brca mutations.
CLINICAL MODULATION OF THE POLY(ADP)RIBOSE
PATHWAY: FUTURE PERSPECTIVES
The epigenetic, chromatin remodeling, and transcriptional regu-
latory roles of Parp-1 are necessary to activate a group of genes
under basal conditions and another cohort in response to stim-
uli, such as cell stress. Therefore, inhibiting Parp-1 will potentially
disrupt expression of a wide range of genes, including tumor sup-
pressor genes, which may limit the benefits of Parp inhibitors in
Brca wild-type patients.
That being said, can this pathway be targeted successfully to
treat a broad range of tumors? In our opinion, yes, but we need to
revisit our approach. First, it is clear that Parp-2 can compensate
for Parp-1. Thus Parp inhibitors should be tested for their capacity
to block the activity of both proteins before being considered for
clinical trials. Such consideration might have prevented the failed
clinical trials with iniparib, a drug initially described as a Parp
inhibitor, but that has recently been proven to lack such activity
(Patel et al., 2012).
Second, the concept of Brcaness needs to be more clearly
defined using both genetic and epigenetic markers. It is proba-
ble that tumors with epigenetically silenced, as well as mutated,
DNA repair genes will be sensitive to Parp inhibitors. This
concept may also be employed to predict successful combina-
tions of chemotherapeutics with Parp inhibitiors. Further, it
is possible that epigenetic silencing of tumor suppressor genes
that are Parp targets may negate any pro-proliferative effects
of Parp, potentially rendering the cells sensitive to Parp inhi-
bition. To date, in vitro models have been used to accurately
predict tumor pathologies that are clinically sensitive to Parp
inhibitors (Bryant et al., 2005; Donawho et al., 2007). There-
fore, future testing of Brcaness models using in vitro systems will
be an important stepping stone to make these models clinically
relevant.
Finally, we propose that Parg represents an attractive
therapeutic target (Figure 2). The understudied protein Parg
catalyzes the counter-activity of Parp-1/2 by removing PARyla-
tion modifications from target proteins. Intriguingly, Parg has a
FIGURE 2 | Comparison of molecular action of Parp inhibitors with
predicted action of Parg inhibitors. (A) Parp inhibitors inhibit the growth of
Brca mutated tumors through blocking DNA damage repair. Parp inhibitors
also dePARylate Ctcf, cause the accumulation of repressive epigenetic marks
at tumor suppressor genes and diminish the expression of these genes. We
propose that these properties of Parp inhibitors will limit their usefulness as
anti-cancer therapeutics. (B) In contrast, we predict Parg inhibitors will
stimulate Ctcf PARylation and the transcription of tumor suppressor genes, in
addition to blocking the DNA damage repair response. Thus, Parg inhibition
may have greater potential as an anti-cancer therapeutic than Parp inhibitors.
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critical role in DNA damage repair, similar to Parp-1 (Fisher et al.,
2007; Mortusewicz et al., 2011). Counter intuitively, while PARy-
lation of target proteins is necessary to initiate the repair response
to DNA damage, removal of these tags is essential for a complete
DNA damage response. Thus, Parg inhibition would likely create a
synthetic lethal situation in Brca defective cells in a similar manner
as Parp inhibitors. Consistent with this concept, Brca mutated
cells have been shown to be highly sensitive to an inhibitor of
Parg (Fathers et al., 2012). Further, we now have exciting new data
demonstrating Parg inhibition is a relevant approach to inhibit the
proliferation of triple-negative breast cancer cell both in vitro and
in vivo (manuscript in preparation).
Parp-1 is an important activator of transcription and proba-
bly plays an important role in promoting transcription of tumor
suppress genes. Therefore, we postulate Parp inhibitors may actu-
ally have pro-oncogenic effects on some cell populations. But,
what is the impact of inhibiting Parg on these same processes?
While the overall impact of Parg on gene regulation remains
unclear at this time, it has been shown that Parg can block Parp-
1 mediated chromatin remodeling and transcriptional activation
in specific circumstances. Therefore, we speculate Parg inhibi-
tion might heighten the effects of PARylation, thus promoting
the transcription of tumor suppressor genes. Further, in cancer
cells having defects in the PARylation pathway such as aberrantly
dePARylated Ctcf, Parg inhibition might serve to correct these
deficiencies.
Supporting these rationale for Parg inhibition being a novel
approach for anti-cancer therapy are several reports indicating
Parg inhibition has potent anti-tumor effects against cholangio-
carinoma in vivo (Marienfeld et al., 2003), and in vitro data
showing growth inhibitory activity of Parg inhibition or knock-
down in multiple types of cancer (Fauzee et al., 2012; Feng et al.,
2012; Li et al., 2012; Pan et al., 2012). Now that the crystal structure
of Parg has been solved (Slade et al., 2011; Kim et al., 2012), there
is a clear need to develop specific inhibitors of this enzyme and
test their efficacy as anti-cancer therapeutics.
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